Rose Leu1, Gillian L Stearns2. 1. University of Vermont Medical Center, 792 College Parkway Ste. 101, Colchester, VT, 05446, USA. 2. University of Vermont Medical Center, 792 College Parkway Ste. 101, Colchester, VT, 05446, USA. Gillian.stearns@uvmhealth.org.
Abstract
PURPOSE OF REVIEW: Adherence to anticholinergic medications is known to be a problem in patients with overactive bladder, with only 13.2% of patients continuing anticholinergic therapy beyond 1 year D'Souza et al. (J Manag Care Pharm. 14:291-301, 2008). RECENT FINDINGS: Prior to the advent of third line therapies such as onabotulinumtoxin A, refractory overactive bladder (OAB) was managed with augmentation cystoplasty, a lengthy surgery with associated side effects including lifetime need for self-catheterization, ileus, and metabolic disturbances. The advent of onabotulinumtoxin A has drastically reduced the rates of augmentation cystoplasties being performed for refractory OAB. However, all procedures are associated with side effects which should be relayed to the patient prior to beginning therapy, as well as their management. In the current review, we summarize the common complications following onabotulinumtoxin A injection as well as their management.
PURPOSE OF REVIEW: Adherence to anticholinergic medications is known to be a problem in patients with overactive bladder, with only 13.2% of patients continuing anticholinergic therapy beyond 1 year D'Souza et al. (J Manag Care Pharm. 14:291-301, 2008). RECENT FINDINGS: Prior to the advent of third line therapies such as onabotulinumtoxin A, refractory overactive bladder (OAB) was managed with augmentation cystoplasty, a lengthy surgery with associated side effects including lifetime need for self-catheterization, ileus, and metabolic disturbances. The advent of onabotulinumtoxin A has drastically reduced the rates of augmentation cystoplasties being performed for refractory OAB. However, all procedures are associated with side effects which should be relayed to the patient prior to beginning therapy, as well as their management. In the current review, we summarize the common complications following onabotulinumtoxin A injection as well as their management.
Authors: Devin N Patel; Juzar Jamnagerwalla; Justin Houman; Jennifer T Anger; Karyn S Eilber Journal: Int Urogynecol J Date: 2017-08-14 Impact factor: 2.894
Authors: Karel Everaert; Jennifer Gruenenfelder; Heinrich Schulte-Baukloh; Russell B Egerdie; Kristin Khalaf; Manher Joshi; Quanhong Ni; David Sussman Journal: Int J Urol Date: 2015-09-22 Impact factor: 3.369
Authors: Yuko M Komesu; Cindy L Amundsen; Holly E Richter; Stephen W Erickson; Mary F Ackenbom; Uduak U Andy; Vivian W Sung; Michael Albo; W Thomas Gregory; Marie Fidela Paraiso; Dennis Wallace Journal: Am J Obstet Gynecol Date: 2017-10-12 Impact factor: 8.661
Authors: Victor W Nitti; David Ginsberg; Karl-Dietrich Sievert; David Sussman; Sidney Radomski; Peter Sand; Dirk De Ridder; Brenda Jenkins; Andrew Magyar; Christopher Chapple Journal: J Urol Date: 2016-03-30 Impact factor: 7.450
Authors: Cindy L Amundsen; Yuko M Komesu; Christopher Chermansky; W Thomas Gregory; Deborah L Myers; Emily F Honeycutt; Sandip P Vasavada; John N Nguyen; Tracey S Wilson; Heidi S Harvie; Dennis Wallace Journal: Eur Urol Date: 2018-02-24 Impact factor: 20.096
Authors: Michael Kennelly; Lonny Green; Nancy Alvandi; Salim Wehbe; John Joseph Smith; Scott MacDiarmid; Jeffrey Mangel; Marc Schwartz; Tamer Aboushwareb; Brian Murray Journal: Curr Med Res Opin Date: 2018-03-20 Impact factor: 2.580
Authors: David James Osborn; Melissa R Kaufman; Stephen Mock; Michael J Guan; Roger R Dmochowski; W Stuart Reynolds Journal: Neurourol Urodyn Date: 2014-06-29 Impact factor: 2.696